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Abstract
Dopamine D1 receptor (DRD1) modulates opioid reinforcement, reward, and opioid-induced neuroadaptation. We propose
that DRD1 polymorphism affects susceptibility to opioid dependence (OD), the efficiency of transition to OD, and opioid-
induced pleasure response. We analyzed potential association between seven DRD1 polymorphisms with the following
traits: duration of transition from the first use to dependence (DTFUD), subjective pleasure responses to opioid on first use
and post-dependence use, and OD risk in 425 Chinese with OD and 514 healthy controls. DTFUD and level of pleasure
responses were examined using a semi-structured interview. The DTFUD of opioid addicts ranged from 5 days to 11 years.
Most addicts (64.0%) reported non-comfortable response upon first opioid use, while after dependence, most addicts
(53.0%) felt strong opioid-induced pleasure. Survival analysis revealed a correlation of prolonged DTFUD with the minor
allele-carrying genotypes of DRD1 rs4532 (hazard ratios (HR) = 0.694; p= 0.001) and rs686 (HR= 0.681, p= 0.0003). Binary
logistic regression indicated that rs10063995 GT genotype (vs. GG+TT, OR = 0.261) could predict decreased pleasure
response to first-time use and the minor alleles of rs686 (OR= 0.535) and rs4532 (OR= 0.537) could predict decreased post-
dependence pleasure. Moreover, rs686 minor allele was associated with a decreased risk for rapid transition from initial use
to dependence (DTFUD#30 days; OR = 0.603) or post-dependence euphoria (OR= 0.603) relative to major allele. In
conclusion, DRD1 rs686 minor allele decreases the OD risk by prolonging the transition to dependence and attenuating
opioid-induced pleasure in Chinese.
Citation: Zhu F, Yan C-x, Wen Y-c, Wang J, Bi J, et al. (2013) Dopamine D1 Receptor Gene Variation Modulates Opioid Dependence Risk by Affecting Transition to
Addiction. PLoS ONE 8(8): e70805. doi:10.1371/journal.pone.0070805
Editor: Huiping Zhang, Yale University, United States of America
Received April 26, 2013; Accepted June 21, 2013; Published August 16, 2013
Copyright:  2013 Zhu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the National Science Foundation of China (No. 81172903), the Fundamental Research Funds for the Central
Universities (2010), the Scientific Research Foundation of Education Ministry and HR Ministry of China for the Returned Overseas Scholars for C-XY. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: yanchunxia@mail.xjtu.edu.cn (C-XY); shbinlee@mail.xjtu.edu.cn (SBL)
Introduction
Opioid dependence (OD) is a complex disease influenced by
both environmental and genetic factors [1]. Linkage and
association studies have partially revealed the molecular basis of
the heritability of OD [2]. However, many of the identified gene
variations could not be replicated by independent studies [2]. The
discrepancy could reflect genetic heterogeneity and/or minimal/
moderate effects of any single gene. Distinct subtypes of the
diagnosis with heterogeneous genetic determinants may have also
contributed to the inconsistent observations [3,4,5]. Classification
of opioid users into more homogeneous subgroups with clinical
and/or pathophysiological features could help to identify involved
genetic factors [5].
The duration for transition from first use to dependence
(DTFUD) varies dramatically among addicts [6], and may
determine addictive liability in particular subjects [7]. Animal
experiments revealed varying vulnerability in transition to
dependence [8] and an association of the transition to persistent
impairment in synaptic plasticity [9]. Although several environ-
mental factors have been reported to affect DTFUD [10], recent
studies suggest that genetic factors play more important role in the
transition to dependence [2,11]. However, few susceptibility genes
affecting the transition to dependence have been identified to date.
Euphoria induced by drugs of abuse is a critical drive for drug
use and seeking [12]. The inter-individual variability in the
strength of pleasure response on first heroin use has been
attributed to m-opioid receptor gene polymorphism [13]. The
subjective pleasure response is a product of opioid rewarding
property. Opioid rewarding effects can be intensified by repeated
drug exposure [14,15]. The pleasure response to opioid is more
dependent on the drug-induced changes in brain reward circuitry
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after dependence than in early use. Relative to response to early
use, the post-dependence response reflects more stably genetic
vulnerability to reward dysregulation caused by opioid [16].
Reward processing depends on dopaminergic neurotransmission
[17]. Previous studies indicated that genetic variations in
dopaminergic pathway could affect the reward process, subjective
response, and susceptibility to dependence [18].
Dopamine receptor D1 (DRD1) is a possible susceptibility gene
for OD. A recent study found that a single nucleotide polymor-
phism (SNP) (rs265975) located at 5 kb downstream of DRD1 is
associated with opiate abuse in Caucasians [19]. DRD1 polymor-
phism (rs4532, rs686, and rs265981) has also been associated with
substance dependence [20,21], addictive behavior [22], and
psychiatric diseases [23,24]. The rs686 polymorphism affects
DRD1 expression and may influence the DRD1 activation in
prefrontal cortex [20,25].
In the current study, we examined DTFUD and subjective
response to opioid on first use and post-dependence use in 425
opioid addicts via retrospective investigation. We genotyped seven
possibly functional SNPs in the DRD1 regulatory and coding
regions in these addicts and 514 healthy controls. We evaluated
the relationships between DRD1 polymorphisms and DTFUD, the
response to opioid on first use, post-dependence, and risk for OD.
Experimental Procedure
2.1 Samples
The present study included 425 unrelated opioid addicts
registered in the Methadone Maintenance Treatment Program
at Xi’an Mental Health Center of China. The OD diagnosis was
established using DSM-IV criteria and based on medical record,
urine test, and interview (Fig. 1). The controls consisted of 514
unrelated healthy persons who had never been diagnosed with
substance abuse and mental illness. All subjects participated
voluntarily and signed written informed consent prior to the
enrollment. This study was approved by the Medical Ethics
Committee of Xi’an Jiaotong University.
2.2 Assessment of opioid-abuse traits
The following measures were obtained from medical records
and a semi-structured interview: age at first opioid use, age of
onset (AOO) of dependence, DTFUD, reasons for first opioid use,
types of OD (heroin vs. opium poppy), administration route of first
use and post-dependence use (nasal inhalation, intravenous or
muscle injection), and opioid dosage. The DTFUD was defined as
the duration from the initial opioid use to first occurrence of the
dependence syndrome according to DSM-IV. The AOO and
DTFUD were assessed by an interviewer and blindly verified by
an independent psychiatrist using medical records and information
provided by first-degree relatives, only the consistent data from
these three sources were included in analysis (Fig. 1). Subjects who
used drugs less than three times per week in the first month or
could not obtain drugs for more than one week were excluded
from the DTFUD analysis.
Subjective responses to opioid on first use and after dependence
were examined using a method previously described with slight
modification [13]. In brief, we asked the addicts to report their
feelings on first-time opioid use and after the dependence using a
checklist consisting of the following 17 items: ‘‘flushing,’’
‘‘stimulated,’’ ‘‘numb,’’ ‘‘drunken,’’ ‘‘difficult to concentrate,’’
‘‘drowsy,’’ ‘‘coasting or spaced out,’’ ‘‘turning of stomach,’’ ‘‘itchy
skin,’’ ‘‘dry mouth,’’ ‘‘dizzy,’’ ‘‘nauseated,’’ ‘‘really high,’’ ‘‘care-
free or happy,’’ ‘‘relaxed,’’ ‘‘euphoric,’’ and ‘‘without feeling
effects of drug.’’ We classified the addicts into two groups on the
basis of the feelings on first opioid use: comfortable (e.g., getting
really high, happy, euphoric, and relaxed) vs. non-comfortable
(e.g., turning of stomach, dizzy, nauseated, or no impact). We
judged post-dependence responses to opioid based on subjective
feelings occurring most frequently during use. The majority of
addicts reported comfortable feelings, and only a small fraction of
them declared that they could not feel any impact after developing
OD. Based on the strength and frequency of pleasure, we assigned
the addicts often feeling strong pleasure to the ‘‘euphoria’’ group
and the addicts with low comfortable or no obvious feelings to the
‘‘non-euphoria’’ group.
2.3 Selection of polymorphisms
We first sequenced DRD1 gene in 20 subjects randomly selected
from the opioid addicts and screened out 8 SNPs with minor allele
frequencies greater than 0.05. Our previous study [23] indicated
perfect linkage disequilibrium (LD, r2 = 1) for two of the eight pairs
of SNPs (rs265981 and rs686; rs10078714, and rs10078866). We
therefore analyzed the remaining six SNPs in this study. We also
included a well-characterized SNP in the Chinese population at
the 39 terminal of DRD1 (rs4867798; HapMap-HCB database) for
association analysis. The DRD1 gene structure and the relative
position of the seven SNPs are shown in Fig. S1.
2.4 Genotyping
We extracted genomic DNA from peripheral blood mononu-
clear cell using a TIANamp kit (Tiangen Biotech, Beijing, China).
We amplified re-sequenced fragments by polymerase chain
reaction and sequenced the products using an ABI 3730 DNA
analyzer (Applied Biosystems, Foster City, CA, USA). We
genotyped SNPs by MALDI-TOF MS using the MassARRAY
system (Sequenom Inc., San Diego, CA, USA) [26]. Primers used
for above experiments are shown in our previous study [23].
2.5 Statistical analysis
We calculated the power of the study to detect association with
OD risk as previously described [27]. We analyzed categorical
variables, such as gender, education level, OD type, route of drug
administration, allele, genotype, and haplotype with the chi-square
test. We used binary logistic regression to calculate the odds ratio
(OR) and 95% confidence interval (CI) for each independent
association, and to construct a model to predict the subjective
response from polymorphisms and related covariates using a
stepwise strategy.
We examined potential correlation of AOO and DTFUD with
genotype and allele using Kaplan-Meier survival analysis. Survival
curves estimated the probability that individuals had not
experienced dependence over the period of time following first
opioid use or at a certain age after birth. The DTFUD was
regarded as survival time with the scale in days. The origin first is
specified as the time of first opioid use, and the outcome of interest
is first occurrence of the dependence syndrome. Since DTFUD in
most addicts (.95%) was less than 360 days (see results below)
and, the error of recalling increases with the self-reported
DTFUD, we set the follow up time in survival analysis to a
maximum of 360 days. Survival time is 360+ days when it
exceeded 360 days. We compared survival curves using three
methods (Wilcoxon, log rank, and Tarone–Ware tests) that give
varying weight to different phases of follow-up time. We used a
Cox proportional hazard regression model to test significant
findings obtained with Kaplan–Meier analysis and to generate
hazard ratios (HRs) and 95% CIs in a multivariate analysis,
controlling for demographic and clinical features.
DRD1 Polymorphisms and Opioid Dependence
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Hierarchical clustering on phenotype variables was used to
identify subtypes, and for each subtype, logistic regression on
subtype-control data was conducted to identify significant associ-
ations. We corrected multiple testing using a Bonferroni method:
the p-value was divided by the total number of loci and considered
significant at 0.0071. We performed intergroup comparison of
genotype frequency based on codominant, heterosis, dominant, or
recessive minor allele models of inheritance. We computed pair-
wise LD statistics (D9 and r2) and haplotype frequency using
Haploview 4.0 in order to construct haplotype blocks and to
evaluate deviation from Hardy–Weinberg equilibrium (HWE)




Cases and controls were matched on age, gender, level of
education, life with family, and unemployment (p.0.05, Table 1).
Among the 425 opioid addicts, 133 initially developed dependence
for opium poppy (Table 1). The DTFUD was available in 394
addicts, and ranged from 5 days to 11 years. Dependence was
developed in 379 subjects within 360 days of first opioid use. We
determined the subjective responses to opioid on first and post-
dependence use in 394 and 396 addicts, respectively. A total of
64.0% addicts reported non-comfortable response upon first
opioid use. The proportion of non-comfortable declined to
13.4% after the development of OD (p= 8.4610235), and all
claimed no impact other than uncomfortable feelings. A total of
343 addicts reported pleasure response to opioid after dependence.
We assigned 210 reporting frequent high pleasure after opioid use
to the ‘‘euphoria’’ group. We assigned the remaining 133 low
comfortable response addicts and the 53 no impact addicts to the
‘‘non-euphoria’’ group (Table 1).
3.2 Association of DRD1 polymorphism with AOO and
DTFUD
The DRD1 polymorphism was not associated with collective
AOO of OD (combined heroin and opium poppy dependence,
p.0.05). The AOO was significantly earlier for opium poppy
dependence (n = 130, median AOO: 23.4 years) than for heroin
dependence (HD, n = 261, median AOO: 28.1 years,
p,8.3610213 for log rank, Tarone–Ware and Wilcoxon tests).
A Kaplan–Meier survival analysis indicated that only the
rs10063995 genotype was associated with AOO for HD
(p,0.003 for log rank, Tarone–Ware, and Wilcoxon tests).
Heroin-dependent subjects carrying the TT genotype (n = 23,
median AOO: 24.2 years) had earlier AOO than those carrying
GG or GT genotype (n = 240, median AOO: 28.5 years).
The probability for emergence of dependence at a certain time
after first opioid use is shown in Fig. 2A. We used Kaplan–Meier
survival analysis to detect the potential influences of DRD1
polymorphisms and demographic and clinical features on the
DTFUD (Table 2). Subjects carrying the minor allele of rs4532
(Fig. 2B) or rs686 (Fig. 2C) had prolonged DTFUD in comparison
to homozygotes (p,0.001 for each SNP using log rank, Tarone–
Ware, and Wilcoxon tests). We used AOO, OD type, response
after first opioid use, gender, as covariates for a Cox regression.
The minor allele-carrying genotypes of rs4532 and rs686 were
significantly associated with lower risk to develop dependence after
Figure 1. Opioid addicts recruitment and assessment of opioid-abuse traits.
doi:10.1371/journal.pone.0070805.g001
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first opioid use compared to homozygotes (rs4532 HR = 0.694;
rs686 HR = 0.681). Shorter DTFUD was noted in minor allele
homozygotes with rs10078866 (Fig. 2D) and rs4867798 (Fig. 2E;
p,0.005 for each SNP using log rank, Tarone–Ware, and
Wilcoxon tests). There was a significant increased risk to develop
dependence after first opioid use with GG genotype of rs10078866
(vs. AA+AG genotype, HR = 1.875) and TT genotype of
rs4867798 (vs. CC+CT genotype, HR = 1.478). The association
between rs4532 and rs686 and DTFUD was also evident in a
more homogeneous group of 262 HD subjects (results not shown).
3.3 Polymorphisms and the subjective responses to
opioid
Most demographic and opioid abuse-related characteristics
were comparable between different response categories, except for
the reason and opioid route of first use (Table 1). The proportion
of peer pressure as the reason for the opioid use initiation was
lower in subjects with comfortable response than in those with
non-comfortable response (8% vs. 21.9% respectively, p= 0.0005).
With respect to administration route of first drug use, the
frequency of intravenous injection in subjects with comfortable
response was larger than that in non-comfortable response subjects
(9.4% vs. 3.1%, p= 0.007).
We compared the genotype and allele frequencies of DRD1
polymorphisms between groups with different responses to opioid
(Table 3). Allele and/or genotype frequencies at rs5326,
rs10063995, and rs10078866 differed significantly between those
with comfortable vs. non-comfortable responses on first opioid use
(p,0.0071). Decreased risk to develop comfortable response to
opioid after first use was observed in subjects carrying the GA+AA
genotype (OR = 0.500) and A allele (OR = 0.551) of rs5326, the
GT+TT genotype (OR = 0.373), GT genotype (OR = 0.318), and
T allele (OR = 0.502) of rs10063995, as well as the AG+GG
genotype (OR = 0.516) and AG genotype (OR = 0.488) of
rs10078866. The above associations remained significant after
adjustment for AOO, gender, first opioid use reason, initial OD
type, and first opioid use methods. Moreover, the opioid use route
(intravenous injection vs. sniffing, OR = 3.605, 95% CI:
1.391,9.346) is a predictive factor for opioid-induced comfortable
responses.
Table 1. Demographic features of the controls and the opioid addicts stratified by the subjective responses on first use and post-
dependence use.
Variable Total cases Response on first use (n =394) Response after OD (n=396)
Comfortable Non-comfortable Euphoria Non-euphoria
Number 425 138(35.0) 256(65.0) 210(53.0) 186(47.0)
Male gender (%) 365 (85.9) 126 (91.3) 217 (84.8) 179 (85.2) 166 (89.2)
Education
#Junior high school (%) 267 (63.1) 88 (63.8) 151 (59.0) 127 (60.5) 113 (60.8)
$Senior high school (%) 156 (36.9) 50 (36.2) 105 (41.0) 83 (39.5) 73 (39.2)
Live with family (%) 295 (69.4) 92 (66.7) 176 (68.8) 143 (68.1) 126 (67.7)
The unemployed (%) 269 (63.3) 91(65.9) 149 (58.2) 131 (62.4) 111 (59.7)
Age of onset (mean6SD)a 26.566.6 26.866.4 26.466.6 26.666.5 26.466.6
Reason for first use of opioid
Curiousness (%) 222 (55.8) 85 (61.6) 135 (52.7) 110 (52.4) 112 (60.2)
Peer pressure (%) 68 (17.1) 11 (8.0)b 56 (21.9) 36 (17.2) 31 (16.7)
Trouble (%) 64 (16.1) 24 (17.4) 39 (15.2) 38 (18.1) 25 (13.4)
Entertainment (%) 24 (6.0) 10 (7.2) 14 (5.5) 15 (7.1) 9 (4.8)
Physical disease (%) 8 (2.0) 3 (2.2) 5 (2.0) 4 (1.9) 4 (2.2)
Others reasons (%) 12 (3.0) 5 (3.6) 7 (2.7) 7 (3.3) 5 (2.7)
Type of OD
Heroin (%) 292 (68.7) 86 (62.3) 175 (69.2) 137 (66.2) 124 (67.0)
Opium poppy (%) 133 (31.3) 52 (37.4) 78 (30.8) 70 (33.8) 61 (33.0)
Method of first opioid use
Sniffed or smoked (%) 374 (88.0) 122 (88.4) 248 (96.9) 200 (95.2) 172 (92.5)
Injection via vein (%) 21 (4.9) 13 (9.4) 8 (3.1) 7 (3.3) 9 (4.8)
Ineligibles (%) 30 (7.1) 3 (2.2) 0 (0.0) 3 (1.5) 5 (2.7)
Method of opioid use after OD
Sniffed or smoked (%) 127 (32.5) 33 (23.9) 93 (36.5) 63 (30.1) 64 (34.4)
Injection via vein (%) 194 (49.6) 80 (58.0) 111 (43.5) 103 (49.3) 89 (47.9)
Others (%) 70 (17.9) 25 (18.1) 51 (20.0) 43 (20.6) 33 (17.7)
DTFUD (day, median (IQR)) 30 (60) 60 (90) 30 (106) 60 (90) 30 (99)
aAge means the age at the onset of opioid dependence for the cases and the age when they participated in our study for the controls.
bThe values of the variable with significant p-value are marked in bold.
doi:10.1371/journal.pone.0070805.t001
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For the response after dependence, the allele and genotype
frequency of rs4532 and rs686 was significantly different between
euphoria and non-euphoria groups (Table 3, p,0.003). The
decreased risk to acquire opioid-induced euphoria after depen-
dence was associated with the AG+GG genotype (OR = 0.425),
AG genotype (OR = 0.385) and G allele (OR = 0.535) of rs686, the
TC+CC genotype (OR = 0.431), TC genotype (OR = 0.391) and
C allele (OR = 0.537) of rs4532, after adjustment for AOO,
gender, and opioid use route.
3.4 Polymorphisms and the OD risk
No significant HWE deviation was found for any SNP in cases
and controls (p.0.05). The pair-wise LD values of these SNPs and
their haplotype structure were similar to our previous published
results (data not shown) [23]. An analysis of the genotype and
allele frequencies suggested only a trend-level association between
rs686 and OD (p= 0.008,0.025 for different inheritance model;
p.0.0071 after Bonferroni correction) (Table 4). We estimated the
power to detect association with OD in this sample size (425 cases
Figure 2. Kaplan–Meier survival curves representing probability that individuals have not experienced dependence over the
period of time following first opioid use. Total addicts (A), stratified by combined minor allele homozygote and heterozygote vs. major allele of
rs4532 homozygote (B), by combined minor allele homozygote and heterozygote vs. major allele of rs686 homozygote (C), by combined major allele
homozygote and heterozygote vs. minor allele of rs10078866 homozygote (D), by combined major allele homozygote and heterozygote vs. minor
allele of rs4867798 homozygote (E). The numbers of patients who have not experienced dependence at a certain time are shown below x-axis for
each genotype.
doi:10.1371/journal.pone.0070805.g002
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and 514 controls) to be 76–99%, assuming an effect size of 1.6 at a
nominal p= 0.05 for minor allele frequencies ranging from 0.06 to
0.44 (65). An analysis stratified by efficiency of transition to
dependence and subjective response, gender, AOO, and type of
initial OD revealed a significant association between DRD1 and
OD with fast transition (DTFUD#30 days), OD with first
comfortable response, as well as OD with post-dependence
euphoria (Table 4). The subjects carrying the AG, AG+GG
genotype, or G allele of rs686 had decreased risk for OD with fast
transition (OR GA = 0.524, 95% CI: 0.352,0.782; OR
GA+AA = 0.537, 95% CI: 0.365,0.790; OR A allele = 0.603, 95%
CI: 0.426,0.853) and OD with post-dependence euphoria (OR
GA = 0.427, 95% CI: 0.280,0.650; OR GA+AA = 0.490, 95% CI:
0.330,0.727; OR A allele = 0.603, 95% CI: 95% CI: 0.426,0.853)
in comparison to the subjects carrying GG+AA, GG genotypes or
G allele, respectively. The CT and CT+TT genotypes of
Table 2. Associations of DTFUD with DRD1 polymorphisms and demographic and clinical features.
Variable n DTFUD p-value
a
Adjustedb HR (95% CI)
Median IQR LR TW Wil
rs10078866 0.008 0.014 0.021
AA 247 30 150 0.118 0.121 0.143
AG 127 60 76 0.131 0.155 0.185
GG 18 30 53 0.003 0.005 0.008 1.875 (1.163,3.023)
rs10063995 0.226 0.256 0.275
GG 254 30 150 0.263 0.322 0.429
GT 116 45 69 0.051 0.035 0.026
TT 23 30 81 0.110 0.117 0.115
rs5326 0.217 0.203 0.223
GG 228 30 90 0.372 0.417 0.484
GA 140 30 69 0.476 0.386 0.386
AA 24 30 53 0.092 0.079 0.086
rs4532 0.002 0.001 0.001
TT 290 30 76 0.001 0.0002 0.0002 0.694 (0.548,0.878)
TC 89 60 180 0.192 0.118 0.100
CC 13 60 270 0.094 0.060 0.060
rs1799914
GG 333 30 60 0.816 0.743 0.662
GA+AAc 59 30 170
rs686 0.001 0.0003 0.0004
AA 291 30 76 0.0003 0.00009 0.00008 0.681 (0.538,0.862)
AG 88 60 180 0.237 0.165 0.150
GG 13 60 270 0.092 0.058 0.057
rs4867798 0.001 0.001 0.001
CC 113 30 60 0.765 0.934 0.733
CT 197 60 160 0.804 0.965 0.931
TT 82 30 50 0.0005 0.0003 0.0002 1.478 (1.151,1.896)
Typesd
Heroin 258 30 166 0.070 0.261 0.561
Opium 132 30 72
Responsed
Negative 252 30 76 0.241 0.243 0.233
Positive 138 60 90
Gender
Male 343 30 72 0.794 0.923 0.793
Female 51 60 110
aFor genetic variants, p-value was calculated based on codominant, dominant for minor allele, heterosis and recessive for minor allele models of inheritance,
respectively. LR: Log Rank test; TW: Tarone–Ware test; Wil.: Wilcoxon test.
bOnly the positive factors found by Kaplan–Meier were included into Cox regression models to calculate HRs, which were adjusted for AOO, gender, types of initial OD,
and subjective response on first opiate use.
cSince there were a small amount of subjects carrying the AA genotype of rs1799914, the AA and GA genotypes were merged to conduct the statistical test.
dTypes: types of OD; Response: subjective response on first opiate use.
doi:10.1371/journal.pone.0070805.t002
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rs10078866 0.942 0.378 0.096 0.308
AA 320(62.4) 265(62.6) 0.932 131(63.6) 0.820 99(71.7) 0.042 118(56.7) 0.159
AG 172(33.5) 139(32.9) 0.829 63(30.4) 0.423 33(23.9) 0.031 78(37.5) 0.310
GG 21(4.1) 19(4.5) 0.764 13(6.3) 0.211 6(4.3) 0.894 12(5.8) 0.329
Per G allele 214(20.9) 177(20.9) 0.973 89(21.5) 0.787 45(16.3) 0.093 102(24.5) 0.128
rs10063995 0.929 0.670 0.0069 0.729
GG 325(63.5) 274(64.6) 0.716 136(65.4) 0.629 106(76.8) 0.003 129(61.7) 0.658
GT 158(30.9) 126(29.7) 0.705 58(27.9) 0.430 24(17.4) 0.002 65(31.1) 0.949
TT 29(5.7) 24(5.7) 0.998 14(6.7) 0.584 8(5.8) 0.952 15(7.2) 0.441
Per T allele 216(21.1) 174(20.5) 0.760 86(20.7) 0.859 40(14.5) 0.014 95(22.7) 0.494
rs5326 0.717 0.897 0.173 0.563
GG 304(59.8) 242(57.2) 0.417 120(58) 0.644 92(67.2) 0.119 117(56) 0.340
GA 173(34.1) 154(36.4) 0.454 74(35.7) 0.666 41(29.9) 0.362 76(36.4) 0.555
AA 31(6.1) 27(6.4) 0.860 13(6.3) 0.928 4(2.9) 0.144 16(7.7) 0.445
Per A allele 235(23.1) 208(24.6) 0.462 100(24.2) 0.678 49(17.9) 0.063 108(25.8) 0.275
rs4532 0.132 0.056 0.433 0.002
TT 360(70) 315(74.5) 0.133 163(78.7) 0.018 102(74.5) 0.312 169(80.9) 0.003
TC 143(27.8) 95(22.5) 0.061 40(19.3) 0.018 31(22.6) 0.222 33(15.8) 0.001
CC 11(2.1) 13(3.1) 0.368 4(1.9) 0.860 4(2.9) 0.589 7(3.3) 0.344
Per C allele 165(16.1) 121(14.3) 0.295 48(11.6) 0.031 39(14.2) 0.462 47(11.2) 0.019
rs1799914
GG 444(87.4) 359(84.9) 0.264 176(85) 0.396 114(83.2) 0.203 174(83.3) 0.143
AA+ GAb 64(12.6) 64(15.1) 31(15) 23(16.8) 35(16.7)
Per A allele 65(6.4) 65(7.7) 0.278 32(7.7) 0.364 24(8.8) 0.171 35(8.4) 0.182
rs686 0.025 0.005 0.282 0.0002
AA 348(68) 316(74.7) 0.024 166(79.8) 0.001 102(73.9) 0.179 169(81.3) 0.0003
AG 153(29.9) 94(22.2) 0.008 38(18.3) 0.001 32(23.2) 0.122 32(15.4) 0.0001
GG 11(2.1) 13(3.1) 0.373 4(1.9) 0.848 4(2.9) 0.602 7(3.4) 0.343
Per G allele 175(17.1) 120(14.2) 0.086 46(11.1) 0.004 40(14.5) 0.303 46(11.1) 0.004
rs4867798 0.796 0.264 0.271
TT 153(30.1) 120(28.4) 0.559 60(29) 0.764 37(27) 0.478 62(29.7) 0.917
TC 255(50.2) 214(50.6) 0.905 95(45.9) 0.297 79(57.7) 0.121 103(49.3) 0.904
CC 100(19.7) 89(21) 0.609 52(25.1) 0.107 21(15.3) 0.246 44(21.1) 0.824
Per T allele 455(44.8) 392(46.3) 0.503 199(48.1) 0.258 121(44.2) 0.854 191(45.7) 0.678
ap-value was calculated by 263 and 262 chi-squared tests based on codominant, dominant for minor allele, heterosis, and recessive for minor allele models of
inheritance, respectively.
bSince there were a small amount of subjects carrying the AA genotype of rs1799914, the AA and GA genotypes were merged to conduct 262 chi-squared tests.
doi:10.1371/journal.pone.0070805.t004
Table 5. Results of association analysis between DRD1 SNPs and subtypes of OD.
Varible rs10078866 rs10063995 rs5326 rs4532 rs1799914 rs686 rs4867798
Subtype1 0.316 0.145 0.139 0.021 0.161 0.011 0.860
Subtype2 0.018 0.064 0.024 0.027 0.267 0.006* 0.288
Subtype3 0.785 0.498 0.245 0.930 0.613 0.649 0.305
Subtype4 0.055 0.126 0.297 0.003* 0.816 0.007* 0.394
*indicates the significant results after Bonferroni multi-test correction.
doi:10.1371/journal.pone.0070805.t005
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rs10063995 were associated with decreased risk of developing OD
with first comfortable response (OR CT = 0.472, 95% CI:
0.292,0.761; OR CT+TT = 0.525, 95% CI: 0.340,0.810) in
comparison to the CC+TT and CC genotypes, respectively. The
TC and TC+CC genotype of rs4532 were associated with OD
with post-dependence euphoria (OR TC = 0.486, 95% CI:
0.320,0.740; OR TC+CC = 0.553, 95% CI: 0.374,0.820) in
comparison to the AA+GG and AA genotypes, respectively.
We also performed a multivariate cluster analysis on the 398
addicts using 16 clinical measures that characterized their opioid
use and related behaviors, mainly including the AOO, gender,
type of opioid, administration route, daily administration dosage of
opioid before methadone treatment, use times of opioid daily
before methadone treatment, DTFUD, subjective response, and so
on. The cluster analysis resulted in four subgroups of addicts that
were more homogeneous with respect to these clinical measures
within each group (Fig. S2). In particular, these clusters differed
significantly on the subjective responses to opioid, respectively, at
the initial use and after the development of dependence on opioid.
The percentages of subject experiencing comfortable response to
opioid initially subgroup1-4 were 99%, 0, 0, 34%, respectively.
And the percentages of subject experiencing euphoric response to
opioid after dependence in subgroup1-4 were 59%, 98%, 1%,
39%, respectively. We then conducted association tests for each of
the subgroups to identify subgroup-dependent genetic effects that
may be overlooked when all addicts were considered in one group.
Table 5 shows the test results for the detection of main effects.
DRD1 rs686 and rs4532 displayed significant association with
subtype 2 and/or subtype 4.
Discussion
4.1 Fast transition from first opioid use to dependence
and opioid-induced pleasure response affects
predisposition to OD
In the present study, no statistically significant association was
found between DRD1 and OD in the overall analysis. However, the
association became apparent after stratifying based on DTFUD
(faster transition) and opioid-induced subjective response (pleasure
response on first use or post-dependence euphoria). This finding
supported the previous observation that DSM-IV OD classification
is not optimal for genetic mapping [3,4,5], and suggests that fast
transition to dependence, pleasure responses upon first-time use,
and post-dependence euphoria are more heritable traits.
Inheritable predisposition to drug dependence comprises
vulnerability in both initiation of drug use and the transition from
first use to abuse to dependence [2,29]. Both animal experiments
[8,9] and epidemiological investigation [6] indicated that only a
small part of subjects who have taken drugs for a prolonged period
develop dependence. The proportion of the drug users who
develop dependence within 1 year and 10 years after first use is 1%
and 12–13% respectively for alcohol, 1.5% and 8% respectively
for marijuana, and 5.5% and 15–16% respectively for cocaine [6].
Apparently, people with rapid progression from initial use to
compulsive use are more likely to develop dependence [10].
Accordingly, genetic factors that place certain individuals at faster
(or slower) transition more likely promote (or prevent) them to
develop dependence.
Inter-individual variation in the reward process is associated with
personality and temperament [30] as well as susceptibility to drug
dependence [31]. People use drugs mostly due to their inherent
rewarding property, particularly prior to the development of
compulsive use [12]. In general, people with stronger pleasure
responses to drugs have higher vulnerability to eventual dependence.
4.2. Role of DRD1 polymorphisms on the transition from
first opioid use to dependence
Animal experiments indicate drug dosage is an important
determinant for addiction development [32]. The time length but
not accumulative opioid intake amount was selected as the index
for efficiency of transition, because it is the onset time of a specific
event that could be more reliably and accurately recalled than
dose in human retrospective study. To further elevate the
reliability and validity of time assessment, we also executed
cross-examination for self-reported information, including that
from lineal relatives and medical records. Drug availability affects
the measure of DTFUD for transition to dependence. Restriction
of personal freedom and being poor increase DTFUD, but not due
to decreased transition efficiency [2,10]. The DTFUD analysis
included only subjects who used opioid at a frequency of three or
more times per week in the first month after the first use and could
readily obtain the drug to fulfill high validity to measure the
efficiency of transition to dependence.
We found a large variation of DTFUD from 5 days to 11 years.
Our data indicated an association between minor alleles of rs4532
and rs686 and longer DTFUD. Moreover, the homozygote addicts
with the rs10078866 and rs4867798 minor alleles have shorter
DTFUD than non-carriers. These findings represent the first
direct evidence of the influence of transition to dependence by
genetic factors. Notably, rs686 is a functional polymorphism that
influences the expression of DRD1 [25]. The genetic variation of
rs686 from A to G decreases DRD1 expression, and has been
associated with a variety of dopamine-related diseases [20,23,24].
Suppressing D1 receptor function could decrease the efficiency
of transition to dependence. For example, D1 receptor genetic
knockout or pharmacological blockade inhibits cocaine [33] and
heroin self-administration [34]. Morphine self-administration is
also decreased by dopaminergic antagonists [35]. In contrast, the
D1 receptor agonist SKF82958 enhances heroin self-administra-
tion in rhesus monkeys [36].
Stimulation of D1 receptors by opioid initiates a sequence of
molecular events, including c-Fos [37], DFosB [38,39], ERK [40]
and CREB [41] activation, which shape neuron structure and
function [42]. Drug-induced persistent neuroadaptation in reward-
related learning and memory processes, which leads to hypersensi-
tivity to drug-associated cues, impulsive decision-making and
abnormal learned behaviors, are the neurobiological basis for the
transition to dependence [42,43]. A postmortem analysis revealed the
regulatory effects of DRD1 variation on its mRNA expression in
striatum, which were blunted by chronic opioid abuse [19]. In
addition, there is an association between DRD1 variation and
HOMER1b/c protein in the human striatum; its pattern also varies
between opioid abusers and healthy controls [19]. These findings
demonstrate that an interaction between DRD1 variation and opioid
action exists to influence neuroplasticity. Presumably, the variation of
rs686 from A to G prolongs DTFUD by suppressing the function of
D1 receptor to interfere with the activation of downstream
transcriptional factors and the long-term neuroplasticity in brain
motivation and reward-related circuits induced by repeated opioid
use. We propose that rs686 is more likely to be a causative SNP for
the altered DTFUD rather than a marker. The positive association of
rs4532 with DTFUD can be attributed to its complete linkage
disequilibrium with rs686 (r2 = 0.96).
4.3 The effects of polymorphisms in DRD1 on subjective
response to opioid
Our data indicates that polymorphisms in DRD1 modulate
subjective responses to opioid in both the initial phase and post-
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dependence. Decreased pleasure responses on first use were
associated with the minor allele-carrying genotypes rs5326,
rs10063995, and rs10078866. Decreased euphoria after depen-
dence was associated with the minor alleles of rs686 and rs4532, as
well as the genotypes containing these minor alleles. A previous
study [13] demonstrated that subjective responses induced by first-
used heroin were affected by the genetic variants in m-opioid
receptor gene. After m-opioid receptor is activated by opioid, the
dopamine neurons in ventral tegmental area (VTA) are dis-
inhibited via inhibiting GABAergic interneurons in VTA to induce
synaptic dopamine release and the activation of dopamine
receptor in the brain reward circuit [44]. Genetic variation in
dopamine neurotransmission is assumed to alter central dopami-
nergic tone and the reward process [18]. Our results provide
strong evidence that the opioid reward process can be influenced
by DRD1 genetic variants.
Consistent with a previous report [13], we found that the
majority of addicts did not have apparent pleasant feeling upon
first opioid use. In contrast, most addicts felt euphoria upon
exposure after the development of dependence, suggesting
enhanced sensitivity to opioid rewarding effects. Animal experi-
ments confirmed reward sensitization induced by repeated
exposure occurs for a variety of drugs of abuse, which is mediated
by several molecules upregulation in amygdala and striatum
[45,46,47]. The enhanced pleasure responses to opioid after
dependence in humans are similar to reward sensitization in
animal, which, depending on the chronic drug-induced neuro-
plastic changes, specifically upregulates reward function. More-
over, different opioid reward encoding patterns were identified
between drug-naı¨ve and dependent rats and the role of D1
receptor transmission in reward also depends on opioid state [48].
The roles of DRD1 in pleasure process of first opioid use and post-
dependence use may be different, which also explains why initial
pleasure-associated variants are different from post-dependence
pleasure-associated variants. DRD1-dependent signaling mediates
many long-term neuroadaptation in reward circuit which may
participate in opioid reward after dependence [38,39,41,48].
Down-regulating DRD1 using a viral-mediated siRNA in the
nucleus accumbens decreases ethanol-induced behavioral sensiti-
zation as well as ethanol rewarding properties [49]. Since the G
allele of rs686 decreases the expression of DRD1, we speculate that
the signaling of D1 receptor upon repeated opioid exposure is
blunted by the G allele of rs686, so the G allele carrier displayed
significantly decreased reward compared with the A allele.
4.4 DRD1 polymorphisms and OD risk
Jacobs et al. [19] recently reported a trend-level association
between rs686 and OD in Caucasians (p= 0.02). Our comparison
between opioid addicts and controls also revealed a possible
association between rs686 and OD risk (p= 0.008,0.025 for
different inheritance model), which was not significant after
Bonferroni correction. Instead, we carried out a probabilistic
method using different strategy from chi-square test to detect
potential association [50], and still revealed no significant effects of
DRD1 on OD risk (p.0.05, data not shown). The DRD1 rs686
affected the disease susceptibility only in a subgroup of addicts
with fast transition to dependence or euphoria, suggesting the
heritable predisposition to OD is dependent on the varying
subtype and features of dependence. The OD subtype with fast
transition to dependence or euphoria had a greater genetic load
than overall OD. The effect size of rs686 specific for these OD
subtypes was decreased by heterogeneous subtype, which corre-
spondingly decreased power of genetic association analysis. In
conclusion, DRD1 rs686 minor allele decreases OD risk by slowing
down the transition to dependence and attenuating opioid-induced
euphoria.
Supporting Information
Figure S1 Gene structure of human DRD1, showing the
re-sequencing fragments and the relative positions of
the 7 SNPs used in our study. The black squares above the
chart of gene structure indicate the fragments we targeted for re-
sequencing.
(TIF)
Figure S2 Four subgroups of addicts defined by a
multivariate cluster analysis. The columns with different
color indicate the different clinical measures that characterized
opioid use and related behaviors, mainly including the age of
onset, gender, type of opioid, administration route, daily
administration dosage of opioid before methadone treatment,
use times of opioid daily before methadone treatment, DTFUD,
subjective response, and so on.
(TIF)
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